College of Pharmacy and Research Institute of Drug Development, Chonnam National University, Gwangju 500-757, Republic of Korea.
Bioorg Med Chem. 2011 Sep 15;19(18):5311-20. doi: 10.1016/j.bmc.2011.08.006. Epub 2011 Aug 8.
Benzo[3,4]azepino[1,2-b]isoquinolinones were designed and developed as constraint forms of 3-arylisquinolines with an aim to inhibit topoisomerase I (topo I). Ring closing metathesis (RCM) of 3-arylisoquinolines with suitable diene moiety provided seven membered azepine rings of benzoazepinoisoquinolinones. Spectral analyses of these heterocyclic compounds demonstrated that the methylene protons of the azepine rings are nonequivalent. The shielding environment experienced by these geminal hydrogens differs unusually by 2.21ppm. As expected, benzoazepinoisoquinolinones displayed potent cytotoxicity. However, cytotoxic effects of the compounds were not related to topo I inhibition which is explained by non-planar conformation of the rigid compounds incapable of intercalating between DNA base pairs. In contrast, flexible 3-arylisoquinoline 8d attains active conformation at drug target site to exhibit topo I inhibition identical to cytotoxic alkaloid, camptothecin (CPT).
苯并[3,4]氮杂[1,2-b]异喹啉酮被设计和开发为 3-芳基异喹啉的约束形式,目的是抑制拓扑异构酶 I(topo I)。带有合适二烯部分的 3-芳基异喹啉的闭环复分解(RCM)提供了苯并氮杂氮杂异喹啉酮的七个成员的氮杂环。这些杂环化合物的光谱分析表明,氮杂环的亚甲基质子是不等价的。这些偕二氢原子经历的屏蔽环境异常不同,为 2.21ppm。正如预期的那样,苯并氮杂氮杂异喹啉酮显示出很强的细胞毒性。然而,化合物的细胞毒性效应与 topo I 抑制无关,这可以解释为刚性化合物的非平面构象不能插入 DNA 碱基对之间。相比之下,柔性 3-芳基异喹啉 8d 在药物靶位上达到活性构象,表现出与细胞毒性生物碱喜树碱(CPT)相同的 topo I 抑制作用。